Lite Strategy, Inc.
LITSHealthcareNASDAQBiotechnology · Last scanned Sep 7, 2026
Scan Results
Daily timeframeLite Strategy, Inc. a clinical-stage pharmaceutical company, focuses on the development of novel and differentiated therapies for the treatment of cancer. Valued at $38.8M, LITS is a micro-cap name in its sector. The company was formerly known as MEI Pharma, Inc.
Market Cap
$38.8M
Beta
0.04
P/E (TTM)
—
P/E (Fwd)
—
EPS (TTM)
$-2.08
EPS (Fwd)
—
ROE
-159.3%
ROA
-27.7%
Cash
$7.5M
Total Debt
$0
Free CF
-$13.4M
52W Change
-62.0%
Annual Financials
Cash vs Debt
Where LITS stands vs its 150-day and 200-day moving averages
As of the September 3, 2026 close, LITS finished 0.95% below its 150-day moving average ($1.05) and 11.86% below its 200-day moving average ($1.18). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is LITS overbought or oversold?
At the September 3, 2026 close, LITS's RSI(14) was 70.6, in overbought territory (above 70). The MACD histogram was positive, so short-term momentum leaned bullish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
Lite Strategy, Inc. reports $7.5M in cash and $0 in total debt. Free cash flow is running at -$13.4M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. ROE of -159.3% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. Revenue has been uneven over recent years, ranging from $40.7M to $0.
With a beta below 0.7, Lite Strategy, Inc. typically sees smaller price swings than the overall market, offering a degree of stability during turbulent periods. The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. It is important to consider these factors alongside broader market conditions and individual financial goals when reviewing LITS.